targeting of intracellular oncoproteins with peptide-centric cars Targeting intracellular oncoproteins - california-gold-nutrition-collagen-peptides Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs Advancing Cancer Therapy: The Promise of Targeting Intracellular Oncoproteins with Peptide-Centric CARs

warrior-peptides The landscape of cancer immunotherapy is rapidly evolving, with a significant focus on developing novel strategies to combat malignancies that have historically proven resistant to treatment.New Class of CAR-T cells eradicates neuroblastoma in mice A key challenge lies in the fact that the majority of oncogenic drivers are intracellular proteins, which have been largely inaccessible to traditional immunotherapeutic approaches. However, recent advancements in peptide-centric chimeric antigen receptors (PC-CARs) are poised to revolutionize this field by enabling the precise targeting of intracellular oncoproteins. This innovative approach, spearheaded by researchers like M.(PDF) Cross-HLA targeting of intracellular oncoproteins ... Yarmarkovich and others, offers a new paradigm for cancer treatment and holds immense potential for expanding the repertoire of targets available for CAR-based therapies.Retraction Note: Cross-HLA targeting of intracellular ...

The fundamental limitation of conventional CAR-T cell therapy is its reliance on cell-surface antigens. This constraint leaves a vast majority of cancer-driving proteins, located within the cell, unaddressed. Peptide-centric chimeric antigen receptors (CARs), however, overcome this hurdle by recognizing oncoprotein epitopes that are presented on the surface of cells via human leukocyte antigens (HLAs).2024年1月17日—Yarmarkovich M, Marshall QF, Warrington JM, .Targeting of intracellular oncoproteins with peptide-centric CARs. Nature. 2023;623:820–827. This mechanism allows for the indirect detection and subsequent elimination of tumor cells expressing these intracellular targets(PDF) Retraction Note: Cross-HLA targeting of intracellular .... The development of these peptide-centric CARs represents a significant breakthrough, as it unlocks the potential to target a much broader spectrum of cancer-associated proteins.

A notable area of research involves the development of PC-CARs targeting the neuroblastoma oncoprotein PHOX2B. Neuroblastoma, a challenging pediatric cancer, is often driven by specific intracellular proteins. By designing PC-CARs that recognize the PHOX2B oncoprotein presented on HLA molecules, researchers have demonstrated the ability of these engineered T cells to effectively kill tumor cells. Crucially, studies have shown that these CARs can kill tumor cells across multiple HLA allotypes, a significant advancement for cross-HLA targeting of intracellular oncoproteins with peptide-centric CARsNew Kind of CAR T-Cell Changes Scientists' Approach to .... This broad recognition capability is vital, as it increases the likelihood of a patient's immune system being able to respond to the therapy, regardless of their specific genetic makeup.

The strategy behind developing these peptide-centric CARs often involves a sophisticated counter panning strategy using predicted potentially cross-reactive peptides. This meticulous approach ensures that the PC-CARs are highly specific for the intended oncoprotein targets while minimizing off-target effectsThe Structural Principles of PC-CARs Can Expand .... The concept of peptide-centric CARs can target unmutated intracellular proteins is particularly exciting, as it suggests that these therapies could be effective even in cancers where mutations are not readily apparent or targetable. This opens up avenues for treating a wider range of cancers and patient populations.

The implications of this research are profound. The ability to effectively target intracellular oncoproteins has been a long-standing goal in oncology. Peptide-centric CARs offer a concrete solution, providing a means to engage the immune system against targets previously considered unreachable. The work by Yarmarkovich and colleagues, published in journals such as *Nature*, has been instrumental in demonstrating the feasibility and efficacy of this approach.A roadmap for driving CAR T cells toward the oncogenic ... While some early research, such as the article "Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs," has been subject to retraction notes, the underlying scientific principles and the potential of peptide-centric CARs continue to be explored and refined. The ongoing research aims to further optimize the design and function of these CARs, ensuring their safety and efficacy in clinical settings.

In summary, the development of peptide-centric CARs represents a significant leap forward in the fight against cancerWe have discovered the ability of PC-CARsto targetpeptidesacross multiple HLA types, significantly expanding the patient populations eligible for these .... By enabling the targeting of intracellular oncoproteins, these engineered immune cells offer a promising new therapeutic modality. The ability to recognize oncoprotein epitopes presented by HLAs, coupled with the potential for cross-HLA targeting, broadens the applicability of CAR-based therapies. As research progresses, the precision and effectiveness of targeting intracellular oncoproteins with peptide-centric CARs are expected to significantly impact patient outcomes, offering hope for those with cancers that were once deemed untreatable. The exploration of targeting these intracellular targets, including specific oncoproteins like PHOX2B, signifies a new era in personalized and effective cancer immunotherapy.